Introduction {#sec1}
============

HCV infection remains a major global public health burden with an estimated 71 million persons chronically infected.[@bib1]^,^[@bib2] The development of highly effective, well-tolerated, direct-acting antivirals (DAAs) has changed the treatment landscape for HCV. The prevalence of chronic HCV infection is estimated to be 0.9--1.3% in the US, affecting 2.9--4.1 million Americans.[@bib3]^,^[@bib4] In China, the prevalence of chronic HCV infection is estimated at 0.7--1.3%, representing around 9.8--18.2 million people.[@bib3]^,^[@bib4]

Roughly 10--20% of persons with chronic HCV infection will develop cirrhosis after 20--30 years of infection.[@bib5]^,^[@bib6] Once cirrhosis has developed, the annual incidence of hepatocellular carcinoma (HCC) has been reported to be 1--5% and hepatic decompensation to be 3--6%.[@bib5]^,^[@bib6] HCV has been the leading cause of liver transplantation and HCC in the US in the past decade but until recently, little attention has been paid to HCV-related HCC and liver mortality in China.[@bib7]

In 2011, we initiated a prospective parallel cohort study of patients with chronic HCV infection in the US and in China to compare the incidence and risk factors of disease progression. We found that at enrolment, a significantly higher proportion of American patients had cirrhosis, hepatic decompensation, and HCC than the Chinese patients.[@bib8] Although these differences may be partly explained by an earlier peak in HCV infection in the US or referral bias, other factors may be contributory and longitudinal studies are needed to confirm whether these differences hold true. The aims of the current analysis are to determine the incidence and associated factors of liver outcomes during follow-up of these 2 cohorts of patients.

Materials and methods {#sec2}
=====================

This study was reported according to the STROBE statement.

Study design, setting, and participants {#sec2.1}
---------------------------------------

This was a prospective study of 2 parallel cohorts of patients with chronic HCV infection recruited in Ann Arbor, US (University of Michigan Health System, UMHS) and in Beijing, China (Peking University Health Science Center, PUHSC). Patients in the UMHS cohort were recruited in the hepatology clinics (general hepatology, liver transplant, and liver tumour) at the University of Michigan in Ann Arbor, and patients in the PUHSC cohort were recruited from 3 sites, Peking University People\'s Hospital in Beijing, and Gu\'an and Kuangcheng clinics in Hebei province. Details of the study design have been reported previously.[@bib8]

Inclusion criteria were adult patients (≥18 years old) with chronic HCV infection who were HCV RNA-positive. Patients who had undergone liver transplantation, known co-infection with HIV, life expectancy \<12 months due to extra-hepatic illnesses, or receiving HCV treatment at enrolment, were excluded. Patients were enrolled between September 2011 and July 2015. This analysis included patients without HCC at enrolment and had at least 1 follow-up visit after enrolment. Patients with cirrhosis were evaluated every 6 months whereas those without cirrhosis were evaluated every 12 months. Follow-up was continued until development of HCC, liver transplantation, death, withdrawal of consent, or end of study visits in December 2017.

Patients enrolled in both countries were evaluated using an identical protocol. Protocol, surveys, and data forms were developed in English and then translated into Chinese. Each patient enrolled in both countries completed the same questionnaire at enrolment. A web-based database with both English and Chinese versions was created and accessible to both teams; data was uploaded every night and stored at a UMHS server.

All patients provided written informed consent before enrolment in the study. The study was approved by the institutional review board or ethics committee at both the University of Michigan and Peking University, the latter provides regulatory oversight for studies done at the Hebei sites; the study complied with the provisions of ICH Good Clinical Practice guidelines.

Clinical parameters and follow-up {#sec2.2}
---------------------------------

Demographic (race/ethnicity, age, sex), clinical (medical history, current medications, and family history of liver disease and HCC), and laboratory data (blood counts, liver panel including albumin \[ALB\], aspartate and alanine aminotransferase \[AST, ALT\], total bilirubin \[TBIL\], alkaline phosphatase \[ALP\], creatinine, international normalized ratio \[INR\], alpha fetoprotein \[AFP\], HCV genotype, HCV RNA, HBsAg, antibody to HBcAg \[anti-HBc\]), and abdominal imaging (ultrasound, computed tomography \[CT\], magnetic resonance imaging \[MRI\]), liver elastography, and liver histology results were collected through structured history taking and medical record review at baseline and at each follow-up visit.

Risk factors for HCV infection, and alcohol, tobacco, coffee, and tea consumption were assessed using a standardized questionnaire. Regular alcohol use was defined as at least 1 drink/day, regular tobacco use was at least 1 cigarette/day, and regular coffee or any kind of tea consumption at least 1 cup/day.

Obesity was defined using race-adjusted cut-off for body mass index (BMI).[@bib9]^,^[@bib10] For Americans, overweight was defined as BMI 25--30, and obesity as BMI ≥30 kg/m^2^. For Chinese patients, overweight was defined as BMI 24--28, and obesity as BMI ≥28 kg/m^2^. Diabetes was defined by medical history or use of medications for treatment of diabetes, and for those with no history of diabetes by fasting blood glucose ≥126 mg/dl or random blood glucose ≥200 mg/dl.[@bib11]^,^[@bib12]

Start and stop dates of HCV treatment, treatment regimen, and dates when sustained virologic response for 12 weeks (SVR12) was achieved were recorded. Availability of interferon-free DAA treatments in the US and in China were considered to be 10 October 2014 and 24 April 2017, respectively, based on first approval of interferon-free DAA regimens.

Assessment of liver cirrhosis and outcomes {#sec2.3}
------------------------------------------

Patients were categorized as having chronic hepatitis, compensated cirrhosis, or decompensated cirrhosis using standardized criteria at both centres. Diagnosis of decompensated cirrhosis was based on evidence of ascites, variceal bleeding, or hepatic encephalopathy. Diagnosis of compensated cirrhosis was based on histology when available. In the absence of biopsy results, diagnosis of compensated cirrhosis was based on 2 of the following 4 criteria: radiological imaging showing features of cirrhosis (nodular liver, intra-abdominal varices or splenomegaly), platelet count \<1000/μl in the absence of other explanations, liver stiffness measurement \>13 kPa based on vibration-controlled transient elastography (FibroScan, Echosens, Paris, France), and gastro-oesophageal varices on endoscopy.

The primary outcome of this study is a composite of liver events. Composite liver outcomes for patients without baseline decompensation were liver-related deaths (LrD), HCC, liver decompensation, or liver transplantation (LT). Composite liver outcomes for patients with baseline decompensation were LrD, HCC, or LT. Follow-up was stopped after patients developed HCC or underwent LT but follow-up continued for those who developed clinical decompensation. HCC was diagnosed by histology whenever possible and in the absence of histology, by triple-phase CT or MRI per the American Association for the Study of Liver Diseases guidelines.[@bib13]

Source documents supporting the diagnosis of cirrhosis and HCC were collected and investigators from UMHS and PUHSC audited the documents from the other centre to confirm these diagnoses.

Statistical analyses {#sec2.4}
--------------------

Data were analysed using SAS 9.4 (SAS Institute, Cary, NC). Categorical data are presented as number and percent and continuous data as mean and standard deviation or median and interquartile range (IQR) as appropriate. We used *t* test or Mann-Whitney *U* test to compare continuous data depending on distribution of data and chi-square test to compare categorical data. Incidence and 95% CI of composite liver outcomes were estimated with an exact method based on the Poisson distribution. We applied competing-risk analysis (Fine and Gray model[@bib14]) to the Cox proportional hazards model to identify independent factors associated with composite liver outcomes, with non-LrD as competing risk event and SVR as a time-dependent covariate. Time-dependent analysis was used to prevent immortal time bias and to minimize confounders, as patients who are most likely to achieve SVR may be least likely to experience liver outcomes. Three candidate competing-risk models were fitted for the multivariate models: model 1, baseline age, sex, SVR, and variables with *p* values \<0.1 in the univariate model; model 2 replaced AST and platelet with AST to platelet ratio index (APRI); model 3 replaced bilirubin, INR, and creatinine with model for end-stage liver disease (MELD). Akaike Information Criterion (AIC)[@bib15] was used to compare these models and the model with the lowest AIC was selected to be the model of best fit.

Analyses were initially performed for the combined cohort and then separately for the UMHS and the PUHSC cohorts, and stratified for baseline cirrhosis and hepatic decompensation. Values of *p* \<0.05 were considered statistically significant.

Results {#sec3}
=======

Characteristics of the UMHS and PUHSC cohorts {#sec3.1}
---------------------------------------------

There were 1000 patients enrolled in the UMHS cohort and 957 in the PUHSC cohort. After we excluded 167 patients with baseline HCC and 140 with no follow-up after enrolment, the remaining 795 UMHS patients and 854 PUHSC patients were included in this analysis ([Fig. 1](#fig1){ref-type="fig"}A, B).Fig. 1Flow chart of patient selection and composite liver outcomes stratified by baseline liver disease stage.(A) UMHS cohort and (B) PUHSC cohort. Number of outcome events = number of new decompensation + total number of (HCC + liver-related death + liver transplantation). HCC, hepatocellular carcinoma; LrD, liver-related deaths; LT, liver transplantation; PUHSC, Peking University Health Science Center; UMHS, University of Michigan Health System.

Most (79.3%) UMHS patients were non-Hispanic white, and 87.9% PUHSC patients were Han Chinese. UMHS patients were significantly more likely to be men (57.4% *vs.* 48.2%), older (median age 57 *vs.* 53 years), obese, diabetic, report current or past use of alcohol, cigarettes, and coffee, and less likely to be anti-HBc positive (31.2% *vs.* 46.4%) ([Table 1](#tbl1){ref-type="table"}). At enrolment, a significantly higher percentage of UMHS patients had cirrhosis (45.4% *vs.* 16.2%) and hepatic decompensation (10.9% *vs.* 4.4%). Diagnosis of compensated cirrhosis was based on histology in 71.9% in the UMHS cohort, and in 4.0% in the PUHSC cohort. The majority of the remaining UMHS patients were diagnosed based on radiology plus thrombocytopenia whereas most PUHSC patients were diagnosed based on radiology plus liver stiffness measurement. Patients who did not meet criteria for cirrhosis at enrolment were deemed not to have cirrhosis. Of these, 62.4% of the UMHS patients had biopsies excluding cirrhosis and 99.7% of PUHSC patients had FibroScan liver stiffness measurements \<13 kPa. The UMHS patients had higher baseline AST, ALT, ALP, TBIL, INR, APRI,[@bib16] and fibrosis-4 markers (FIB-4)[@bib17] than the PUHSC cohort ([Table 1](#tbl1){ref-type="table"}). These differences persisted in the subgroup who did not meet our diagnostic criteria of cirrhosis at enrolment except for TBIL and FIB-4, indicating liver disease was more advanced in the UMHS cohort even among the non-cirrhosis subgroup (data not shown).Table 1Baseline characteristics of patients in UMHS and PUHSC cohorts.UMHS cohort (n = 795)PUHSC cohort (n = 854)*p* valueAge (years)57.0 (52.0--60.0)53.0 (47.0--59.0)\<0.0001Sex (female)339 (42.6%)442 (51.8%)0.0002BMI[a](#tbl1fna){ref-type="table-fn"}\<0.0001 Underweight or normal199 (25.0%)395 (46.2%) Overweight280 (35.2%)308 (36.1%) Obese316 (39.7%)151 (17.7%)Diabetes169 (21.3%)81 (9.5%)\<0.0001Alcohol\<0.0001 Never307 (38.6%)620 (72.6%) Current/past use488 (61.4%)234 (27.4%)Smoking\<0.0001 Never180 (22.6%)552 (64.6%) Current/past use615 (77.4%)302 (35.4%)Coffee\<0.0001 Never298 (37.5%)816 (95.5%) Current/past use497 (62.5%)38 (4.4%)Tea\<0.0001 Never614 (77.2%)565 (66.2%) Current/past use181 (22.8%)289 (33.8%)HCV genotype\<0.0001 Non-genotype 1127 (16.2%)239 (28.5%) Genotype 1655 (83.8%)598 (71.4%)Anti-HBc\<0.0001 Negative544 (68.8%)458 (53.6%) Positive247 (31.2%)396 (46.4%)Platelet (1,000/μl) \<100211 (26.5%)131 (15.5%)\<0.0001 ≥100584 (73.5%)712 (84.5%)ALT (U/L)60.0 (41.0, 94.0)43.0 (28.0, 68.0)\<0.0001AST (U/L)60.0 (41.0, 95.0)40.0 (28.0, 62.0)\<0.0001ALP (U/L)96.0 (75.0, 131.0)80.0 (64.0, 98.0)\<0.0001AFP (ng/ml)5.2 (2.9, 12.0)3.4 (2.2, 6.0)\<0.0001Albumin (g/dl) \<3.064 (8.1%)11 (1.3%)\<0.0001 ≥3.0730 (91.9%)836 (98.7%)Total bilirubin (mg/dl)\<0.0001 \<2.0714 (89.9%)812 (96.0%) ≥2.080 (10.1%)34 (4.0%)INR \<1.2548 (73.0%)723 (96.8%)\<0.0001 ≥1.2203 (27.0%)24 (3.2%)Liver disease stage\<0.0001 No cirrhosis434 (54.6%)716 (83.8%) Compensated cirrhosis274 (34.5%)100 (11.7%) Decompensated cirrhosis87 (10.9%)38 (4.4%)APRI\<0.0001 \<1.0386 (48.5%)593 (70.3%) 1.0--1.595 (11.9%)85 (10.1%) \>1.5314 (39.5%)165 (19.6%)FIB-4\<0.0001 \<1.45152 (20.2%)244 (32.8%) 1.45--3.25244 (32.5%)310 (41.7%) ≥3.25355 (47.3%)189 (25.4%)MELD score Compensated cirrhosis0.38 \<10190 (69.8%)65 (74.7%) ≥1082 (30.1%)22 (25.3%) Decompensated cirrhosis\<0.0001 \<1554 (62.1%)36 (97.3%) ≥1533 (37.9%)1 (2.7%)SVR[b](#tbl1fnb){ref-type="table-fn"}0.19 Never achieved358 (45.0%)412 (48.2%) Achieved437 (55.0%)442 (51.8%)[^2][^3][^4][^5]

During follow-up, 493 UMHS and 502 PUHSC patients received HCV treatment; of these, 430 (87.2%) UMHS and 211 (42.0%) PUHSC patients received interferon-free DAA regimens. SVR was achieved in 437 (55% overall and 88% of those treated) UMHS patients and 442 (51.7% overall and 86.8% of those treated) PUHSC patients. The proportions of patients who achieved SVR in the 2 cohorts was comparable for patients with decompensated cirrhosis (16.1% *vs.* 21.0%) or compensated cirrhosis (47.4% *vs.* 49.0%), but higher in UMHS patients with no cirrhosis at enrolment (67.5% *vs.* 53.8%, *p* \<0.0001) ([Table 2](#tbl2){ref-type="table"}).Table 2Incidence of composite liver outcomes in the UMHS and PUHSC cohorts stratified by baseline cirrhosis status.UMHS cohortPUHSC cohortNo. at risk[a](#tbl2fna){ref-type="table-fn"}No. of outcomes (%)[b](#tbl2fnb){ref-type="table-fn"}Incidence (95% CI)[c](#tbl2fnc){ref-type="table-fn"}No. at risk[a](#tbl2fna){ref-type="table-fn"}No. of outcomes (%)[b](#tbl2fnb){ref-type="table-fn"}Incidence (95% CI)[c](#tbl2fnc){ref-type="table-fn"}**SVR as time-dependent variable**No cirrhosis All43420 (4.6)1.4 (1.0--2.2)7162 (0.03)0.1(0.02--0.3) B-SVR43417 (3.9)1.5 (0.9--2.4)7162 (0.03)0.8 (0.02--0.3) A-SVR2943 (1.0)1.2 (0.4--3.6)3850 (0.0)n.a.Compensated cirrhosis All27490 (32.8)10.6 (8.7--13.1)10028 (28.0)8.4(5.8--12.2) B-SVR27474 (27.0)11.3 (9.0--14.2)10027 (27.0)9.7 (6.7--14.1) A-SVR15016 (10.7)8.3 (5.1--13.5)511 (2.0)1.9 (0.3--13.2)Decompensated cirrhosis All8746 (52.9)27.4 (20.5--36.6)3817 (44.7)15.9 (9.9--25.6) B-SVR8745 (51.7)30.1 (22.5--40.3)3817 (44.7)16.7 (10.4--26.9) A-SVR141 (7.1)5.4 (0.7--38.7)80 (0.0)n.a.Total All795156 (19.6)6.5 (5.6--7.6)85447 (5.5)1.4 (1.1--1.9) B-SVR795136 (17.1)7.0 (5.9--8.3)85446 (5.4)1.6 (1.2--2.1) A-SVR45820 (4.3)4.3 (2.8--6.6)4441 (0.2)0.2 (0.03--1.6)**SVR as time-fixed variable**No cirrhosis All43420 (4.6)1.4 (1.0--2.2)7162 (0.3)0.1(0.02--0.3) Non-SVR14117 (12.1)4.1 (2.6--6.6)3312 (0.6)0.2 (0.04--0.7) SVR2933 (1.0)0.3 (0.1--1.0)3850 (0.0)n.a.Compensated cirrhosis All27490 (32.8)10.6 (8.7--13.1)10028 (28.0)8.4(5.8--12.2) Non-SVR14474 (51.4)25.1 (20.0--31.5)5127 (52.9)21.5 (14.7--31.3) SVR13016 (12.3)2.9 (1.8--4.7)491 (2.0)0.5 (0.07--3.5)Decompensated cirrhosis All8746 (52.9)27.4 (20.5--36.6)3817 (44.7)15.9 (9.9--25.6) Non-SVR7345 (61.6)38.3 (28.6--51.3)3017 (56.7)22.2 (13.8--35.8) SVR141 (7.1)2.0 (0.3--14.1)80 (0.0)n.a.Total All795156 (19.6)6.5 (5.6--7.6)85447 (5.5)1.4 (1.1--1.9) Non-SVR358136 (38.0)16.5 (13.9--19.5)41246 (11.2)3.4 (2.5--4.5) SVR43720 (4.6)1.3 (0.8--2.0)4421 (0.2)0.05 (0.01--0.4)[^6][^7][^8][^9]

Among the patients who did not receive treatment, 126 UMHS and 45 PUHSC patients reached an outcome, and 0 UMHS and 297 PUHSC patients were lost to follow-up, prior to the availability of interferon-free DAA regimens.

Incidence of composite liver outcomes {#sec3.2}
-------------------------------------

After a total follow-up of 5709 person-years (2398 for UMHS cohort and 3311 for PUHSC cohort), 203 patients had experienced a composite liver outcome (156 in the UMHS cohort and 47 in the PUHSC cohort) ([Fig. 1](#fig1){ref-type="fig"}). Of these 203 patients, 48 had developed HCC, 45 had LrD, 15 had LT, and 95 had new decompensation as the first liver-related outcome. Thirty-five patients (25 UMHS and 10 PUHSC) had more than 1 liver-related outcome.

The overall incidence of composite liver outcomes was 3.6/100 person-year (95% CI: 3.1--4.1), and was significantly higher in the UMHS cohort: 6.5/100 person-year (95% CI: 5.6--7.6) than the PUHSC cohort: 1.4/100 person-year (95% CI: 1.1--1.9). The cumulative incidence (95% CI) of composite liver outcomes after 1, 3, and 5 years of follow-up was 7.7% (6.1--9.7%), 17.9% (15.2--21.1%), and 25.3% (22.0--29.1%) in the UMHS cohort and 1.8% (1.3--2.5%), 4.5% (3.4--6.0%), and 6.6% (5.0--8.6%) in the PUHSC cohort, respectively ([Fig. 2](#fig2){ref-type="fig"}A).Fig. 2Cumulative incidence of composite liver outcomes for UMHS *vs.* PUHSC cohorts.Among (A) all patients, (B) patients with no cirrhosis, (C) patients with compensated cirrhosis, and (D) patients with decompensated cirrhosis. PUHSC, Peking University Health Science Center; UMHS, University of Michigan Health System.

Stratification by cirrhosis status at enrolment showed that incidence of composite liver outcomes was higher in the UMHS cohort only in the subgroup without cirrhosis at enrolment, whereas there was no difference in the subgroups with compensated cirrhosis or the subgroups with decompensated cirrhosis. The incidence of composite liver outcomes per 100 person-years was lowest among patients without baseline cirrhosis (1.4 UMHS and 0.1 PUHSC) followed by those with baseline compensated cirrhosis (10.6 UMHS and 8.4 PUHSC) and patients with baseline decompensated cirrhosis (27.4 UMHS and 15.9 PUHSC). The cumulative 5-year incidence (95% CI) of composite liver outcomes in the UMHS and PUHSC cohorts was 6.7% (4.3--10.4%) and 0.3% (0.1--1.2%) for those without cirrhosis at enrolment ([Fig. 2](#fig2){ref-type="fig"}B), 40.1% (33.8--47.4%) and 34.2% (25.5--45.9%) for those with baseline compensated cirrhosis ([Fig. 2](#fig2){ref-type="fig"}C), and 60.5% (49.8--73.5%) and 49.6% (36.8--66.8%), respectively for patients with baseline decompensated cirrhosis ([Fig. 2](#fig2){ref-type="fig"}D).

SVR and composite liver outcomes {#sec3.3}
--------------------------------

Patients who achieved SVR during the study period were significantly less likely to develop composite liver outcomes than those who did not achieve SVR (4.6% *vs.* 38.0% UMHS and 0.2% *vs.* 11.2% PUHSC cohorts, [Table 2](#tbl2){ref-type="table"}). However, liver outcomes continued to occur albeit at lower rates after achieving SVR, particularly in patients with baseline cirrhosis ([Table 2](#tbl2){ref-type="table"}). Among patients without baseline cirrhosis, 19 patients (17 UMHS and 2 PUHSC) developed 23 composite liver outcomes (10 decompensation, 10 HCC, 1 LT, and 2 LrD) before achieving SVR, and only 3 patients (all from UMHS) developed composite liver outcomes (decompensation) after achieving SVR. Among patients with baseline compensated cirrhosis, 101 patients (74 UMHS and 27 PUHSC) developed 126 composite liver outcomes (71 decompensation, 27 HCC, 1 LT, and 27 LrD) before achieving SVR, whereas 17 patients (16 UMHS and 1 PUHSC) developed 20 composite liver outcomes (11 decompensation, 8 HCC, 0 LT, and 1 LrD) after achieving SVR. Of the patients with baseline decompensated cirrhosis, 62 (45 UMHS and 17 PUHSC) developed 62 composite liver outcomes (13 HCC, 15 LT, and 34 LrD) before achieving SVR, whereas only 1 patient (from UMHS) developed composite liver outcome (LrD) after achieving SVR ([Table 2](#tbl2){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}).

Factors associated with composite liver outcomes among patients with no cirrhosis or compensated cirrhosis {#sec3.4}
----------------------------------------------------------------------------------------------------------

Events included in composite liver outcomes in the subgroups with no cirrhosis or compensated cirrhosis at enrolment were different from those with baseline decompensated cirrhosis because patients with baseline decompensation could not have decompensation as an outcome. Thus, 2 separate analyses were performed to identify risk factors for composite liver outcomes. Univariate competing-risk analysis with SVR as a time-dependent variable of the combined UMHS and PUHSC cohorts without cirrhosis or compensated cirrhosis at enrolment identified older age, obesity, diabetes, current/past consumption of alcohol, genotype 1 HCV, higher ALT, AST, ALP, AFP, TBIL, INR, APRI, and FIB-4 were associated with a higher risk of composite liver outcomes, whereas higher ALB and platelet count were associated with a lower risk of composite liver outcomes.

For multivariate competing-risk analysis, we fitted 3 candidate models and selected the model with the lowest AIC to be the best fit model ([Table 3](#tbl3){ref-type="table"}). For patients with no cirrhosis or compensated cirrhosis at enrolment, model 2 had the best fit, with older age, diabetes, lower ALT, higher ALP, TBIL, INR and APRI, and baseline cirrhosis associated with a higher risk of composite liver outcomes but study site and SVR was not ([Fig. 3](#fig3){ref-type="fig"}A). When patients with no cirrhosis and compensated cirrhosis were analysed separately, higher ALP, TBIL, and APRI and lower ALB were associated with a higher risk of composite liver outcomes in patients with no cirrhosis at enrolment whereas study site, age, and SVR showed a trend (model 2 in [Table 3](#tbl3){ref-type="table"} and [Fig. 3](#fig3){ref-type="fig"}B). Among patients with baseline compensated cirrhosis, older age, higher TBIL, ALP, and INR, and lower platelet count and ALB were associated with a higher risk of composite liver outcomes but study site and SVR were not (model 1 in [Table 3](#tbl3){ref-type="table"} and [Fig. 3](#fig3){ref-type="fig"}C). Results of separate multivariate competing-risk analysis for UMHS cohort and PUHSC cohort are shown in [Figs. S1](#appsec1){ref-type="sec"}A--C and [S2](#appsec1){ref-type="sec"}A, B.Table 3Akaike Information Criterion (AIC) of multivariate competing-risk models of composite liver outcomes with SVR as time-dependent variable.UMHSPUHSCTotalPatients with no cirrhosis Model 1126.993--167.176 Model 2**119.026**--**161.083**Patients with compensated cirrhosis Model 1**873.346**196.609**1,170.361** Model 2879.698196.2491,173.550 Model 3887.139**166.026**1,188.741Patients with no cirrhosis or compensated cirrhosis Model 11,090.594**202.025**1,401.481 Model 2**1,086.626**204.872**1,397.824** Model 31,114.404204.4191,418.132Patients with decompensated cirrhosis Model 1363.04798.426521.862 Model 2**362.344**100.409524.889 Model 3366.383**89.330520.623**[^10][^11]Fig. 3Multivariate competing risk analysis of factors associated with composite liver outcomes for combined UMHS and PUHSC cohorts.Among (A) patients with no cirrhosis or compensated cirrhosis, (B) patients with no cirrhosis, (C) patients with compensated cirrhosis, and (D) patients with decompensated cirrhosis. Results shown for variables with *p* value \<0.05 and variables of interest: cohort, sex, age, and SVR (as time-dependent variable) from the multivariate analysis. ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; LT, liver transplantation; MELD, model for end-stage liver disease; PUHSC, Peking University Health Science Center; SVR, sustained virologic response; TBIL, total bilirubin; UMHS, University of Michigan Health System.

Factors associated with composite liver outcomes among patients with decompensated cirrhosis {#sec3.5}
--------------------------------------------------------------------------------------------

For the subgroup with baseline decompensated cirrhosis, univariate analysis showed that UMHS site, male sex, higher TBIL, higher MELD, and lower ALB were associated with a higher risk of composite liver outcomes, whereas study site and SVR were not. Model 3 had the best fit in multivariate analysis ([Table 3](#tbl3){ref-type="table"}) and results showed that male sex, higher MELD, lower ALB, and absence of SVR were associated with a higher risk of composite liver outcomes ([Fig. 3](#fig3){ref-type="fig"}D). Achievement of SVR was associated with 80% lower risk of composite liver outcomes.

Separate analysis for each cohort showed higher MELD was associated with a higher risk of composite liver outcomes in the UMHS cohort whereas male sex and higher MELD were associated with a higher risk of composite liver outcomes in the PUHSC cohort ([Figs. S1](#appsec1){ref-type="sec"}D and [S2](#appsec1){ref-type="sec"}C).

Discussion {#sec4}
==========

In this parallel cohort study of patients with chronic HCV infection recruited from UMHS in the US and PUHSC in China, we found a higher percentage of UMHS patients had cirrhosis, hepatic decompensation, or HCC at enrolment, and a significantly higher incidence of liver outcomes defined as hepatic decompensation, HCC, LT, or LrD during follow-up, compared with the PUHSC patients. After stratification by cirrhosis status at enrolment, these differences persisted only in the subgroups of patients who did not have cirrhosis at enrolment. Further inspection found that UMHS patients not diagnosed to have cirrhosis at enrolment had more advanced liver disease (higher APRI, INR) than PUHSC patients. Our data suggest that UMHS and PUHSC patients with chronic HCV infection had similar rates of progression of liver disease but UMHS patients had more advanced liver disease at enrolment. We hypothesize that the latter is related to a longer duration of infection in the UMHS patients. Among the patients with a presumed source of infection, the estimated median duration of infection in the UMHS cohort was 33 years compared with 23 years in the PUHSC cohort.[@bib8] This corresponds to an earlier peak of HCV infection in the US (1970s) than in China (1980s).

In this study, we used a composite of hepatic decompensation, HCC, LT, or LrD as outcome because the incidence of individual events was low. As expected, severity of liver disease at enrolment was the most important factor associated with outcomes, with highest incidence in the subgroup with decompensated cirrhosis, followed by the subgroup with compensated cirrhosis and then the subgroup with no cirrhosis. Markers of more advanced liver disease were also predictive of outcomes within each subgroup.

Among the patients who did not have hepatic decompensation at enrolment, those with compensated cirrhosis had 5.0-fold higher risk of liver outcomes than those without cirrhosis. Few patients in the UMHS cohort had liver elastography and few patients in the PUHSC cohort had liver biopsies; thus, diagnosis of compensated cirrhosis was based on a combination of criteria and some patients not meeting our criteria for cirrhosis diagnosis might have compensated cirrhosis. Indeed, we found that among the subgroup not diagnosed to have cirrhosis at enrolment, lower ALB and higher TBIL, ALP, and APRI were associated with higher incidence of outcomes. Of note, although only 20 of 979 patients with baseline APRI \<1.0 had outcomes, the risks were 4.7-fold and 14.9-fold higher in those with APRI 1.0--1.5 and \>1.5, respectively. In this subgroup without cirrhosis at enrolment, UMHS study site had a trend toward a higher incidence of outcomes whereas achievement of SVR had a trend toward a lower incidence of outcomes.

Besides liver disease severity, other factors may contribute to differences in rates of disease progression in the UMHS and PUHSC cohorts. The UMHS cohort was more obese, more likely to be diabetic, and to be current/past alcohol and tobacco users than the PUHSC cohort; however, these factors were not associated with incidence of composite clinical outcomes in the combined cohort or the individual cohorts on multivariate analysis.

HCV treatment with achievement of SVR has been shown to result in significant decrease in incidence of HCC, liver decompensation, listing for LT, and liver-related mortality.[@bib18], [@bib19], [@bib20] Interferon-free DAA treatments became available in the US earlier than in China. Despite differences in availability of DAAs, SVR rates were similar in the 2 cohorts, likely due to a lower percentage with cirrhosis and a high percentage with favourable IL28B genotype in the PUHSC cohort, allowing a high proportion of PUHSC patients treated with interferon-based therapies to achieve SVR.[@bib21]

Antiviral therapy improved outcomes of patients with chronic HCV infection, especially when SVR is achieved.[@bib22]^,^[@bib23] We examined the impact of SVR on liver outcomes both as a time-fixed variable and a time-dependent variable. When SVR was analysed as a time-fixed variable, incidence of composite liver outcomes was \>10-fold lower in those who did *vs.* those who did not achieve SVR for each subgroup ([Table 2](#tbl2){ref-type="table"}). We acknowledge that patients who are more likely to achieve SVR tend to have less advanced liver disease and therefore are less likely to have liver outcomes. To prevent immortal bias and to minimize confounders, we analysed the impact of SVR as a time-dependent variable. Using time-dependent analysis, incidence of composite liver outcomes was lower after achievement of SVR but the difference was not statistically significant, likely due to the short duration of post-SVR follow-up, median (IQR) of 1.0 (0.3--1.6) years for UMHS cohort and 0 (0--1.9) for PUHSC cohort ([Table 2](#tbl2){ref-type="table"}). However, we found a significant benefit on outcomes in the subgroup with decompensated cirrhosis, likely because these patients were at greatest risk of short-term outcomes. Improved SVR rate and safety of DAAs have led to the treatment of patients with decompensated cirrhosis. Several clinical trials have shown SVR rates higher than 80%, and significant improvement of Child-Pugh-Turcotte score/MELD score in some patients.[@bib24], [@bib25], [@bib26] In this study, among the patients with decompensated cirrhosis at enrolment, only 1 patient (1/22; 4.5%) died of liver disease and none developed HCC after achieving SVR.

The strengths of our study are the use of common protocol, manual of operation, and database as well as verification of outcomes through review of source documents, permitting comparison of outcomes in patients with chronic HCV infection in the US and China. However, there are several limitations to this study. First, although roughly 800 patients were included in each cohort, the number is relatively small and is a convenience sample recruited from research sites that may not be representative of patients with HCV in the US or China. Second, the methods used for diagnosis of cirrhosis varied and some patients not diagnosed to have cirrhosis at enrolment might have compensated cirrhosis. Third, the duration of follow-up was short, in particular the duration of post-SVR follow-up, limiting our ability to study the long-term impact of SVR. Fourth, interferon-free DAAs were not available at the beginning of the study; thus, most patients with decompensated cirrhosis and some with compensated cirrhosis could not be treated and a substantial proportion of patients had outcomes before the availability of interferon-free DAAs. Finally, antiviral therapy was not administered in a standardized manner but rather driven by local physician practice. Therefore, there may have been bias in who was treated and the type of treatment used at both sites.

In summary, our study suggests that despite differences in host and environmental factors, incidence of liver outcomes was similar in UMHS and PUHSC patients with chronic HCV infection after accounting for liver disease severity at enrolment. We found that stage of liver disease at enrolment was the most important factor in predicting outcomes. We also showed a benefit of SVR on reducing clinical outcomes in patients with decompensated cirrhosis at enrolment. With increasing availability of DAA therapies not only in the US but also in China, and decrease in costs of DAAs in both countries, our data highlight the need for early diagnosis, linkage to care, and treatment of hepatitis C in its early stages to prevent liver outcomes and to meet the World Health Organization goal of eliminating HCV by 2030.
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[^5]: SVR was a time-fixed variable here.

[^6]: A-SVR, after SVR; B-SVR, before SVR; n.a., not applicable; PUHSC, Peking University Health Science Center; SVR, sustained virologic response; UMHS, University of Michigan Health System.

[^7]: Number of patients at risk.
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